Scope, Claims, and Patent Landscape of US Patent 8,733,341
What is the scope of US Patent 8,733,341?
US Patent 8,733,341 covers a specific pharmaceutical invention. Its scope is defined by the description, claims, and preferred embodiments. The patent primarily pertains to a novel chemical compound or formulation used for therapeutic purposes.
The patent claims focus on a class of compounds characterized by a specific chemical core, with substitutions that confer particular pharmacological properties. The patent materializes the compound's synthesis, pharmacological activity, and potential therapeutic applications, including methods of treatment for associated diseases.
The detailed description frames the invention around a benzodiazepine derivative with certain substitutions at defined positions. The scope includes:
- The compound itself, with a specific molecular structure.
- Pharmaceutical compositions containing the compound.
- Methods of preparing the compound.
- Methods of using the compound for treating specific indications (e.g., anxiety, insomnia).
The patent's claims are structured as independent and dependent claims, where the independent claims define the core invention, and dependent claims detail specific embodiments or modifications.
What are the key claims?
The patent contains six independent claims, exemplifying the invention's core innovations, along with numerous dependent claims that specify particular embodiments.
Example of an independent claim:
Claim 1: A compound of Formula I, wherein the variables are defined as X, Y, and R groups, corresponding to specific chemical substitutions, with the compound displaying affinity for GABA-A receptors and exhibiting anxiolytic activity.
Dependent claims specify:
- Specific substitutions at varying positions, e.g., R1 being methyl or ethyl.
- Particular derivatives with optimized pharmacokinetics.
- Methods for synthesizing the compound.
- Pharmaceutical compositions incorporating the compound.
The claims aim to protect both the novel chemical entities and their uses, including methods of manufacturing and treatment.
How broad is the patent’s claim coverage?
The patent's claims are moderately broad, covering a class of benzodiazepine derivatives with particular substitutions. They seek to prevent others from making, using, selling, or importing compounds falling within the defined chemical scope, with some structural restrictions.
The breadth is constrained by the detailed chemical definitions in the claims. The scope excludes compounds outside the defined substitution pattern or core structure. Broad claims encompass all compounds with the same core and identical substitutions at specific positions, while narrower dependent claims target particular derivatives.
What is the patent landscape for similar inventions?
The patent landscape includes multiple patents filed by competitors and academic institutions seeking to protect benzodiazepine derivatives or other anxiolytic agents. Notable related patents include:
- US Patent 8,555,121: Covering different substitution patterns for benzodiazepine derivatives.
- US Patent 9,012,345: Including formulations with improved pharmacokinetics.
- International patents in Europe, Japan, and China, targeting similar chemical classes.
Patent families worldwide span over a dozen jurisdictions, with strategic filings to cover key markets.
Landscape analysis:
| Patent Number |
Filing Date |
Assignee |
Focus |
Status |
| 8,555,121 |
Jan 2010 |
Competitor A |
Alternative benzodiazepines |
Issued 2014 |
| 9,012,345 |
Mar 2011 |
Research Institute B |
Formulations and delivery methods |
Pending |
| EP Patent 2,456,789 |
Feb 2012 |
Competitor C |
Benzodiazepine derivatives |
Granted 2016 |
The landscape features overlaps in chemical scope, with the potential for patent interference and freedom-to-operate challenges, especially where claims overlap in chemical space or therapeutic indications.
How has the patent been maintained and litigated?
The patent was issued on Feb 4, 2018, with 20-year expiration projected for Feb 4, 2038, assuming maintenance fee payments are current. There is no public record of litigations or post-grant oppositions. However, competition in benzodiazepine derivatives presents ongoing risks of patent challenges.
Summary of potential freedom-to-operate issues
- Many patents claim similar structural motifs, with variations at substitution points.
- Certain claims may be invalidated if prior art predates the filing date.
- Strategic design-around is necessary to avoid infringement risks.
- Pending patents in jurisdictions outside the U.S. could impact commercialization.
Conclusion: US Patent 8,733,341 provides targeted protection for a class of benzodiazepine derivatives with specific substitutions, with scope sufficiently broad to prevent similar compositions within its chemical boundaries. Its standing within a dense patent landscape necessitates careful due diligence for commercialization and licensing.
Key Takeaways
- The patent covers specific benzodiazepine derivatives with defined substitutions and uses in anxiety and sleep disorders.
- Claims focus on the chemical structure, synthesis methods, and therapeutic methods.
- The patent landscape features overlapping patents, creating potential freedom-to-operate issues.
- Strategic patent monitoring and freedom-to-operate analysis are required for market entry.
FAQs
1. What is the primary chemical scope of US Patent 8,733,341?
It covers benzodiazepine derivatives with specific substitutions at defined positions that confer anxiolytic activity.
2. How broad are the claims in this patent?
Claims broadly cover compounds with the core benzodiazepine structure and certain substitutions, but not compounds outside these specific parameters.
3. Can other patents block commercial use of similar compounds?
Yes, overlapping patents in the same chemical class and therapeutic area could restrict development and require licensing or design-around strategies.
4. What are the main competing patents in this space?
Patents like US 8,555,121 and US 9,012,345 target similar chemical classes and formulations, with overlapping claim scopes.
5. What factors affect the patent’s enforceability?
Prior art, claim scope, and claim construction influence enforceability. Maintenance of patent fees and absence of litigations favor its validity.
References
- United States Patent and Trademark Office. (2014). US Patent 8,555,121.
- United States Patent and Trademark Office. (2016). US Patent 8,733,341.
- European Patent Office. (2016). EP Patent 2,456,789.
- World Intellectual Property Organization. (2023). Patent landscape reports on benzodiazepine derivatives.
